Minivelle (Estradiol transdermal System)

MINIVELLE® (estradiol transdermal system), the world’s smallest estrogen therapy patch developed and manufactured by Noven Pharmaceuticals, is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause and for the prevention of postmenopausal osteoporosis. It is available in five dosage strengths (0.025, 0.0375, 0.05, 0.075 and 0.10 mg/day). The 0.025 strength is indicated only for the prevention of postmenopausal osteoporosis.

Ingredients

DIPROPYLENE GLYCOL (UNII: E107L85C40) OLEYL ALCOHOL (UNII: 172F2WN8DV) POVIDONE K30 (UNII: U725QWY32X)

Cautions

MINIVELLE should not be used if you have unusual vaginal bleeding, currently have or have had certain cancers, had a stroke or heart attack, currently have or have had blood clots, currently have or have had liver problems, have been diagnosed with a bleeding disorder, are allergic to MINIVELLE or any of its ingredients, or think you may be pregnant. Before you take MINIVELLE, tell your healthcare provider if you have unusual vaginal bleeding, have any other medical conditions, are going to have surgery or will be on bed rest, are breast feeding, and about all of the medicines you take. MINIVELLE should be used at the lowest effective dose and for the shortest duration consistent with your treatment goals and risks. You and your healthcare professional should talk regularly about whether you still need treatment with MINIVELLE. The most common side effects that may occur with MINIVELLE are headache, breast tenderness, back and limb pain, common cold, upset stomach, nausea, inflammation of the sinuses and irregular vaginal bleeding or spotting. These are not all the possible effects of MINIVELLE. Please read the Patient Information section within the full Prescribing Information before taking MINIVELLE . For more information ask your healthcare provider or pharmacist for advice about side effects.